Back to Research Home
AMGNAmgen Inc
Health Care · Biotechnology · Mega
$439.26−1.79%
As of 23 Oct 2026Mkt cap $239B
Stage 13
WAIT
Fundamentals
43.0/75
Technical
6.0/15
Independent
49.0/90
GCAE viewtechnical state requires waiting rather than entering now
Price
- 1M
- +8.2%
- 3M
- +16.7%
- 6M
- +27.5%
- 1Y
- +48.4%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 27.3xHist median 25.8x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 15.4%
- Operating margin
- 24.7%
- FCF margin
- 22.0%
- Current ratio
- 1.1x
Growth
- Revenue growth
- +10.0%Latest FY YoY
- Revenue CAGR
- +9.1%
- EPS CAGR
- +8.5%
- FCF CAGR
- −0.8%
Capital
- Share-count trend
- +0.4%3Y annualised
- Net debt
- $41.7B4.2x OCF
Annual trend
- CAGR 2021–2025
- +9.1%
- Latest · 2025
- $37B
- YoY
- +10.0%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
technical state requires waiting rather than entering now
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-03
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded